Compare NLY & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NLY | BBIO |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 15.3B |
| IPO Year | N/A | 2019 |
| Metric | NLY | BBIO |
|---|---|---|
| Price | $21.21 | $71.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 24 |
| Target Price | $23.45 | ★ $85.43 |
| AVG Volume (30 Days) | ★ 7.7M | 1.6M |
| Earning Date | 04-21-2026 | 04-28-2026 |
| Dividend Yield | ★ 13.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $188.83 | $88.16 |
| Revenue Next Year | $2.40 | $74.13 |
| P/E Ratio | $7.88 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $16.60 | $30.08 |
| 52 Week High | $24.52 | $84.94 |
| Indicator | NLY | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 52.60 |
| Support Level | $20.43 | $70.65 |
| Resistance Level | $23.27 | $78.20 |
| Average True Range (ATR) | 0.49 | 2.64 |
| MACD | 0.04 | 0.38 |
| Stochastic Oscillator | 38.02 | 55.27 |
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are: the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.